1. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States
- Author
-
Raj Patel, Sandeep S. Saluja, Caroline Yang, Robert G. Micheletti, Megan H. Noe, Adela R. Cardones, Sasha Stephen, Lindy P. Fox, Mark D.P. Davis, Scott Worswick, Jennifer Boggs, Alba Posligua, Daniel D. Miller, Jessica St. John, Monica Rani, Misha Rosenbach, Ronald Hamrick, Arash Mostaghimi, Arturo R. Dominguez, Baran Ho, Bernice Y. Kwong, Lauren C. Hughey, Maria Aleshin, Kanade Shinkai, Erika M. Summers, Larry M. Jones, David J. Margolis, Zelma Chiesa-Fuxench, Daniela Kroshinsky, Benjamin H. Kaffenberger, Karolyn A. Wanat, Jonathan Cotliar, Amy Musiek, Natalie Sun, Victoria R. Sharon, Joel M. Gelfand, Shayna Gordon, Nicole Strickland, Jennifer K. Chen, Ashwin Agarwal, Kimball Jade Kindley, David A. Wetter, and Alex G. Ortega-Loayza
- Subjects
Adult ,Male ,medicine.medical_specialty ,Critical Care ,Sulfamethoxazole ,Dermatology ,Biochemistry ,Trimethoprim ,Cohort Studies ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Adrenal Cortex Hormones ,Internal medicine ,Intensive care ,medicine ,Humans ,Molecular Biology ,Survival analysis ,Aged ,Retrospective Studies ,business.industry ,Immunoglobulins, Intravenous ,Retrospective cohort study ,Cell Biology ,Middle Aged ,medicine.disease ,Survival Analysis ,United States ,Toxic epidermal necrolysis ,Standardized mortality ratio ,Stevens-Johnson Syndrome ,030220 oncology & carcinogenesis ,Female ,business ,Cohort study ,medicine.drug - Abstract
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe mucocutaneous reaction with few large cohorts reported. This multicenter retrospective study included patients with SJS/TEN seen by inpatient consultative dermatologists at 18 academic medical centers in the United States. A total of 377 adult patients with SJS/TEN between January 1, 2000 and June 1, 2015 were entered, including 260 of 377 (69%) from 2010 onward. The most frequent cause of SJS/TEN was medication reaction in 338 of 377 (89.7%), most often to trimethoprim/sulfamethoxazole (89/338; 26.3%). Most patients were managed in an intensive care (100/368; 27.2%) or burn unit (151/368; 41.0%). Most received pharmacologic therapy (266/376; 70.7%) versus supportive care alone (110/376; 29.3%)-typically corticosteroids (113/266; 42.5%), intravenous immunoglobulin (94/266; 35.3%), or both therapies (54/266; 20.3%). Based on day 1 SCORTEN predicted mortality, approximately 78 in-hospital deaths were expected (77.7/368; 21%), but the observed mortality of 54 patients (54/368; 14.7%) was significantly lower (standardized mortality ratio = 0.70; 95% confidence interval = 0.58-0.79). Stratified by therapy received, the standardized mortality ratio was lowest among those receiving both steroids and intravenous immunoglobulin (standardized mortality ratio = 0.52; 95% confidence interval 0.21-0.79). This large cohort provides contemporary information regarding US patients with SJS/TEN. Mortality, although substantial, was significantly lower than predicted. Although the precise role of pharmacotherapy remains unclear, co-administration of corticosteroids and intravenous immunoglobulin, among other therapies, may warrant further study.
- Published
- 2018
- Full Text
- View/download PDF